Cite
HARVARD Citation
Fischer, M. et al. (n.d.). Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population. European journal of cancer. pp. S49-S50. [Online].